Accelerate assay development and reduce cycle times for AAV quantification in complex biological samples
Available on demand

Assessing AAV vector quality in gene therapy manufacturing is crucial, but the current gold standard, serotype-specific ELISA, has its drawbacks — time-consuming and prone to matrix effects. In this webinar, Dr. Yoann Saucereau from ExcellGene reveals how a label-free approach not only cut down on complexities in biological matrices but also enabled a quick, routine method. Now, ExcellGene effortlessly analyzes up to 96 samples in under 30 minutes for efficient AAV platform development.

Key learning objectives

  • Explore how suitable QC workflows are established in AAV development and manufacturing
  • Discover the critical role of assay design and development to determine correct binding kinetics, affinity values or analyte concentrations
  • Consider the optimization and evaluation of an AAV titer assay in comparison to Octet® AAVX Biosensors

Who should attend?

  • Lab researchers

Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

Sartorius Group